Compare FMC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMC | AAPG |
|---|---|---|
| Founded | 1910 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | N/A |
| Metric | FMC | AAPG |
|---|---|---|
| Price | $11.85 | $17.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $18.50 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 2.7M | 8.8K |
| Earning Date | 04-29-2026 | 05-20-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,727,800,000.00 | N/A |
| Revenue This Year | $7.89 | $290.34 |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $16.92 |
| 52 Week High | $44.68 | $48.45 |
| Indicator | FMC | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 37.96 |
| Support Level | N/A | N/A |
| Resistance Level | $14.31 | $27.98 |
| Average True Range (ATR) | 0.65 | 0.74 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 36.44 | 16.43 |
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.